Clinical Trial Update: A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update of ramucirumab administered subcutaneously in participants with advanced solid tumors; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Ramucirumab (LY3009806) (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Advanced Solid Tumor | Phase 1 | Status: TERMINATED | Results posted: 2023-02-27